Beijing CanalLotus Biotech Co.,Ltd.
+86 15810288723
Lang. :
English
☰
Home
Global Drug Supply
International Purchasement of Comparator
Exportation of R&D Drugs
Comparator Import & Export
Storage and Logistics of Investigational Product
Repackage of The Investigational Product
Clinical Trial Subjects Recruitment
Global Partner
R&D Products
News
Latest News
NDA News
Clinical News
Industrial News
Company Update
About
About CanalLotus Biotech
Milestones
Facilities Gallery
Clinical Viewpoint
Talent Recruitment
R&D center
Production base
Home
News
· All Photo
· Storage & Distribution
storage-5
CanalLotus
•
2019/11/26
550
•
storage-5
Return
Hot Info
FDA Approves Simtriyo (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD)
FDA Approves Garzulys (insulin aspart-fsan), a Biosimilar to NovoLog
FDA Approves Tylenol with Naproxen (acetaminophen and naproxen sodium) for Over-the-Counter Treatment of Pain
FDA Approves Lipfendra (enlicitide) Oral PCSK9 Inhibitor to Reduce LDL-C in Adults with Hypercholesterolemia
FDA Approves Sarclisa Escena (isatuximab-irfc) Subcutaneous Injection for the Treatment of Multiple Myeloma
FDA Approves Avsola (infliximab-axxq), a Biosimilar to Remicade
FDA Approves Talicia (omeprazole magnesium, amoxicillin and rifabutin) for the Treatment of H. pylori Infection in Adults
FDA Approves Ziextenzo (pegfilgrastim-bmez), a Biosimilar to Neulasta
FDA Approves Reblozyl (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions
FDA Approves Brukinsa (zanubrutinib) for the Treatment of Mantle Cell Lymphoma
PellePharm Completes Enrollment Of Pivotal Phase 3 Clinical Trial Of Patidegib Topical Gel In Patients With Gorlin Syndrome
Positive Phase III Results for Genentech’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in the New England Journal of Medicine
The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing
New England Journal of Medicine Publishes Results of Ebola Clinical Trial Confirming Superiority of Regeneron's REGN-EB3 to ZMapp in Preventing Ebola Deaths
Chi-Med Announces Surufatinib Granted FDA Orphan Drug Designation for Pancreatic Neuroendocrine Tumors
15810288723
